{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T04:04:48Z","timestamp":1793678688547,"version":"4.5.1"},"reference-count":37,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T00:00:00Z","timestamp":1761177600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca PLC","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002973","name":"Daiichi-Sankyo","doi-asserted-by":"publisher","award":["DS-8201"],"award-info":[{"award-number":["DS-8201"]}],"id":[{"id":"10.13039\/501100002973","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinicaltherapeutics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.clinthera.2025.09.019","type":"journal-article","created":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T20:04:42Z","timestamp":1762027482000},"page":"1161-1169","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Real-World Characteristics, Treatment Patterns, and Outcomes in Advanced HER2 (ERBB2)-Mutant Non-Small Cell Lung Cancer: A Retrospective Study of Single Centers in France and Germany"],"prefix":"10.1016","volume":"47","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7966-8980","authenticated-orcid":false,"given":"Petros","family":"Christopoulos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christin","family":"Assmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lirong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyle","family":"Dunton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed","family":"Ali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehmet","family":"Berktas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Delmastro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandria","family":"Str\u00fcbing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Xiong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Lay-Flurrie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pooja","family":"Hindocha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tarana","family":"Mehdikhanova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Girard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2025.09.019_bib0001","author":"Howlander"},{"key":"10.1016\/j.clinthera.2025.09.019_bib0002","unstructured":"World Health Organization (WHO). Lung cancer. https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/lung-cancer (accessed August 23, 2024)."},{"key":"10.1016\/j.clinthera.2025.09.019_bib0003","unstructured":"cBioPortal for cancer genomics. https:\/\/www.cbioportal.org\/study\/summary?id=luad_broad%2Cluad_cptac_2020%2Clung_msk_mind_2020%2Cluad_mskimpact_2021%2Cluad_mskcc_2020%2Cluad_msk_npjpo_2021%2Cluad_mskcc_2015%2Cluad_oncosg_2020%2Cluad_tcga%2Cluad_tcga_pub%2Cluad_tcga_pan_can_atlas_2018%2Cluad_tsp%2Clung_smc_2016%2Clung_nci_2022%2Clusc_cptac_2021%2Clusc_tcga%2Clusc_tcga_pub%2Clusc_tcga_pan_can_atlas_2018%2Cnsclc_ctdx_msk_2022%2Clung_msk_2017%2Cnsclc_mskcc_2018%2Cnsclc_pd1_msk_2018%2Cnsclc_mskcc_2015%2Cnsclc_tracerx_2017%2Cnsclc_unito_2016%2Cnsclc_tcga_broad_2016%2Csclc_clcgp%2Csclc_jhu%2Csclc_ucologne_2015%2Csclc_cancercell_gardner_2017%2Clung_pdx_msk_2021%2Clung_msk_pdx (accessed March 13, 2025)."},{"key":"10.1016\/j.clinthera.2025.09.019_bib0004","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.1111\/1759-7714.13419","article-title":"Mutational landscape and characteristics of ERBB2 in non-small cell lung cancer","volume":"11","author":"Wei","year":"2020","journal-title":"Thorac Cancer"},{"key":"10.1016\/j.clinthera.2025.09.019_bib0005","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.cllc.2024.01.002","article-title":"HER2-mutant advanced and\/or metastatic non\u2013small-cell lung cancer: a US electronic health records database analysis of clinical characteristics, treatment practice patterns, and outcomes","volume":"25","author":"Waliany","year":"2024","journal-title":"Clin Lung Cancer"},{"key":"10.1016\/j.clinthera.2025.09.019_bib0006","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.1007\/s12325-019-01001-9","article-title":"Non-small cell lung cancer patients harboring HER2 mutations: clinical characteristics and management in a real-life setting. Cohort HER2 EXPLORE GFPC 02-14","volume":"36","author":"Auliac","year":"2019","journal-title":"Adv Ther"},{"key":"10.1016\/j.clinthera.2025.09.019_bib0007","doi-asserted-by":"crossref","first-page":"488","DOI":"10.4143\/crt.2022.359","article-title":"Real world characteristics and clinical outcomes of HER2-mutant non\u2013small cell lung cancer patients detected by next-generation sequencing","volume":"55","author":"Ahn","year":"2023","journal-title":"Cancer Res Treat"},{"key":"10.1016\/j.clinthera.2025.09.019_bib0008","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.lungcan.2016.05.030","article-title":"Outcomes of chemotherapies and HER2 directed therapies in advanced HER2-mutant lung cancers","volume":"99","author":"Eng","year":"2016","journal-title":"Lung Cancer"},{"key":"10.1016\/j.clinthera.2025.09.019_bib0009","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1093\/annonc\/mdz167","article-title":"Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry","volume":"30","author":"Mazieres","year":"2019","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clinthera.2025.09.019_bib0010","doi-asserted-by":"crossref","first-page":"4099","DOI":"10.1002\/cncr.30869","article-title":"HER2 mutations in lung adenocarcinomas: a report from the Lung Cancer Mutation Consortium","volume":"123","author":"Pillai","year":"2017","journal-title":"Cancer"},{"key":"10.1016\/j.clinthera.2025.09.019_bib0011","doi-asserted-by":"crossref","first-page":"4380","DOI":"10.1002\/cncr.32461","article-title":"Frequency and outcomes of brain metastases in patients with HER2-mutant lung cancers","volume":"125","author":"Offin","year":"2019","journal-title":"Cancer"},{"key":"10.1016\/j.clinthera.2025.09.019_bib0012","doi-asserted-by":"crossref","first-page":"753","DOI":"10.21037\/tlcr-20-559","article-title":"Exon 20 YVMA insertion is associated with high incidence of brain metastasis and inferior outcome of chemotherapy in advanced non-small cell lung cancer patients with HER2 kinase domain mutations","volume":"10","author":"Yang","year":"2021","journal-title":"Transl Lung Cancer Res"},{"key":"10.1016\/j.clinthera.2025.09.019_bib0013","article-title":"Consensus for HER2 alterations testing in non-small-cell lung cancer","volume":"7","author":"Ren","year":"2022","journal-title":"ESMO Open"},{"key":"10.1016\/j.clinthera.2025.09.019_bib0014","doi-asserted-by":"crossref","first-page":"v1","DOI":"10.1093\/annonc\/mdw326","article-title":"Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"27","author":"Novello","year":"2016","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clinthera.2025.09.019_bib0015","doi-asserted-by":"crossref","first-page":"iv192","DOI":"10.1093\/annonc\/mdy275","article-title":"Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"29","author":"Planchard","year":"2018","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clinthera.2025.09.019_bib0016","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.annonc.2022.12.013","article-title":"Non-oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"34","author":"Hendriks","year":"2023","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clinthera.2025.09.019_bib0017","doi-asserted-by":"crossref","DOI":"10.1177\/1758835920936090","article-title":"Clinical outcomes of patients with HER2-mutant advanced lung cancer: chemotherapies versus HER2-directed therapies","volume":"12","author":"Zhou","year":"2020","journal-title":"Ther Adv Med Oncol"},{"key":"10.1016\/j.clinthera.2025.09.019_bib0018","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1097\/JTO.0b013e31816e2ea3","article-title":"Impact of HER2 gene and protein status on the treatment outcome of cisplatin-based chemoradiotherapy for locally advanced non-small cell lung cancer","volume":"3","author":"Kuyama","year":"2008","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.clinthera.2025.09.019_bib0019","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1186\/1756-9966-28-97","article-title":"The effect of HER2 expression on cisplatin-based chemotherapy in advanced non-small cell lung cancer patients","volume":"28","author":"Calikusu","year":"2009","journal-title":"J Exp Clin Cancer Res"},{"key":"10.1016\/j.clinthera.2025.09.019_bib0020","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1093\/annonc\/mdv573","article-title":"Lung cancer patients with HER2 mutations treated with chemotherapy and HER2-targeted drugs: results from the European EUHER2 cohort","volume":"27","author":"Mazi\u00e8res","year":"2016","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clinthera.2025.09.019_bib0021","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1186\/s12885-018-4277-x","article-title":"Outcomes of pemetrexed-based chemotherapies in HER2-mutant lung cancers","volume":"18","author":"Wang","year":"2018","journal-title":"BMC Cancer"},{"key":"10.1016\/j.clinthera.2025.09.019_bib0022","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1016\/j.jtho.2019.12.129","article-title":"Efficacy and safety of anti\u2013PD-1 immunotherapy in patients with advanced NSCLC with BRAF, HER2, or MET mutations or RET translocation: GFPC 01-2018","volume":"15","author":"Guisier","year":"2020","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.clinthera.2025.09.019_bib0025","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.annonc.2022.12.009","article-title":"Oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"34","author":"Hendriks","year":"2023","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clinthera.2025.09.019_bib0026","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1002\/ijc.32133","article-title":"Combined targeted DNA and RNA sequencing of advanced NSCLC in routine molecular diagnostics: analysis of the first 3,000 Heidelberg cases","volume":"145","author":"Volckmar","year":"2019","journal-title":"Int J Cancer"},{"key":"10.1016\/j.clinthera.2025.09.019_bib0027","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.ctrv.2016.03.009","article-title":"The impact of brain metastasis on quality of life, resource utilization and survival in patients with non-small-cell lung cancer","volume":"45","author":"Peters","year":"2016","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.clinthera.2025.09.019_bib0028","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1093\/annonc\/mdr150","article-title":"Metastatic non-small-cell lung cancer: consensus on pathology and molecular tests, first-line, second-line, and third-line therapy","volume":"22","author":"Felip","year":"2011","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clinthera.2025.09.019_bib0029","doi-asserted-by":"crossref","first-page":"e731","DOI":"10.1093\/oncolo\/oyac114","article-title":"Rationale, strengths, and limitations of real-world evidence in oncology: a Canadian review and perspective","volume":"27","author":"Azoulay","year":"2022","journal-title":"Oncologist"},{"key":"10.1016\/j.clinthera.2025.09.019_bib0030","article-title":"Real-world outcomes of first-line treatment with anti\u2013PD(L)1-based combination therapy for nonsquamous metastatic non\u2013small cell lung cancer: a multiregional chart review in Europe, Japan, and the United States","volume":"10","author":"Liu","year":"2024","journal-title":"JCO Glob Oncol"},{"key":"10.1016\/j.clinthera.2025.09.019_bib0031","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1200\/JCO.23.02744","article-title":"Therapy for stage IV non\u2013small cell lung cancer with driver alterations: ASCO Living Guideline, Version 2023.3","volume":"42","author":"Jaiyesimi","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clinthera.2025.09.019_bib0034","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1056\/NEJMoa2112431","article-title":"Trastuzumab deruxtecan in HER2-mutant non\u2013small-cell lung cancer","volume":"386","author":"Li","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2025.09.019_bib0035","doi-asserted-by":"crossref","first-page":"4852","DOI":"10.1200\/JCO.23.01361","article-title":"Trastuzumab deruxtecan in patients with HER2-mutant metastatic non\u2013small-cell lung cancer: primary results from the randomized, Phase II DESTINY-Lung02 trial","volume":"41","author":"Goto","year":"2023","journal-title":"J Clin Oncol"},{"issue":"Suppl","key":"10.1016\/j.clinthera.2025.09.019_bib0036","doi-asserted-by":"crossref","first-page":"8543","DOI":"10.1200\/JCO.2024.42.16_suppl.8543","article-title":"Trastuzumab deruxtecan (T-DXd) in patients with HER2-mutant metastatic non\u2013small cell lung cancer (mNSCLC): final analysis results of DESTINY-Lung02","volume":"42","author":"Janne","year":"2024","journal-title":"J Clin Oncol"},{"issue":"Suppl","key":"10.1016\/j.clinthera.2025.09.019_bib0037","doi-asserted-by":"crossref","first-page":"S762","DOI":"10.1016\/j.annonc.2023.09.2354","article-title":"Trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2 (ERBB2)-mutant (HER2m) metastatic non\u2013small cell lung cancer (NSCLC) with and without brain metastases (BMs): pooled analyses from DESTINY-Lung01 and DESTINY-Lung02","volume":"34","author":"Li","year":"2023","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clinthera.2025.09.019_bib0038","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1186\/s12885-021-08759-8","article-title":"Pyrotinib combined with thalidomide in advanced non-small-cell lung cancer patients harboring HER2 exon 20 insertions (PRIDE): protocol of an open-label, single-arm phase II trial","volume":"21","author":"Ai","year":"2021","journal-title":"BMC Cancer"},{"issue":"Suppl. 16","key":"10.1016\/j.clinthera.2025.09.019_bib0039","doi-asserted-by":"crossref","first-page":"TPS8654","DOI":"10.1200\/JCO.2024.42.16_suppl.TPS8654","volume":"42","author":"Johnson","year":"2024","journal-title":"J Clin Oncol"},{"issue":"Suppl. 2","key":"10.1016\/j.clinthera.2025.09.019_bib0040","doi-asserted-by":"crossref","first-page":"S873","DOI":"10.1016\/j.annonc.2024.08.1450","article-title":"A randomized phase III trial evaluating oral BAY 2927088, compared with standard of care, as first-line treatment of locally advanced or metastatic NSCLC harboring HER2-activating mutations (SOHO-02)","volume":"35","author":"Passaro","year":"2024","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clinthera.2025.09.019_bib0041","unstructured":"ClinicalTrials.gov. NCT05048797. A study to investigate the efficacy and safety of trastuzumab deruxtecan as the first treatment option for unresectable, locally advanced\/metastatic non-small cell lung cancer with HER2 mutations. Updated 2024. https:\/\/clinicaltrials.gov\/study\/NCT05048797 (accessed January 3, 2025)."}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291825003455?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291825003455?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T05:40:31Z","timestamp":1773812431000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291825003455"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":37,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["S0149291825003455"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2025.09.019","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Real-World Characteristics, Treatment Patterns, and Outcomes in Advanced HER2 (ERBB2)-Mutant Non-Small Cell Lung Cancer: A Retrospective Study of Single Centers in France and Germany","name":"articletitle","label":"Article Title"},{"value":"Clinical Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinthera.2025.09.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}